🇺🇸 FDA
Patent

US 6951917

MHC-class II restricted melanoma antigens and their use in therapeutic methods

expired A61KA61K38/00

Quick answer

US patent 6951917 (MHC-class II restricted melanoma antigens and their use in therapeutic methods) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Sep 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 04 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
61
CPC classes
A61K, A61K38/00